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Abstract
Parenteral nutrition (PN) is indicated in alcoholic steatohepatitis (ASH)
and in cirrhotic patients withmoderate or severemalnutrition. PN should
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Bei Patienten mit Alkoholischer Steatohepatitis (ASH) oder Zirrhose mit
mäßiger oder schwererMangelernährung, die auf oralemoder enteralem
Wege nicht ausreichend ernährt werden können, ist der sofortige Beginn
der PE (parenterale Ernährung) indiziert. ASH- oder Zirrhosepatienten,
die auf oralem oder enteralem Wege ausreichend ernährt werden
können, aber aus medizinischen Gründen eine vorübergehende, über
12 h hinausgehende Nahrungskarenz (nächtliche Nahrungskarenz
mitrechnen) einhalten müssen, sollen eine basale Glukosezufuhr
(2–3 g·kg-1·d-1) erhalten. Dauert diese Karenz länger als 72 h, ist eine
totale PE indiziert. Bei höhergradiger hepatischer Enzephalopathie,
insbesondere bei HE IV, ist bei gestörten Schutzreflexen und ungeschütz-
ten Atemwegen der parenterale Zufuhrweg für die Ernährung in Betracht
zu ziehen. Des Weiteren sollten Zirrhosepatienten oder Patienten nach
einer Lebertransplantation nach einem operativen Eingriff eine frühe
postoperative (zusätzliche) PE erhalten, wenn sie auf oralem oder ente-
ralem Wege nicht ausreichend ernährt werden können. Zur Frage der
Spender- bzw. Organkonditionierungmit dem Ziel derMinimierung eines
Ischämie-/Reperfusionsschadens durch parenterale Gabe vonGlutamin
und Arginin kann keine Empfehlung gegeben werden. Die Indikation
zur künstlichen Ernährung bei akutem Leberversagen ist unabhängig
vom Ernährungszustand dann zu sehen, wenn eine orale Ernährung
innerhalb von 5–7 Tagen nicht wieder aufgenommen werden kann.
Dabei ist in erster Linie die enterale Ernährung über eine nasoduodenale
Sonde anzustreben.
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Alcoholic steatohepatitis (ASH;
alcoholic hepatitis + cirrhosis)
Indication and time of PN in ASH
• PN is indicated in ASH and should be immediately
started in ASH patients with moderate or severe mal-
nutrition, who cannot be sufficiently fed either orally
or enterally (A).
• ASH patients who can be sufficiently fed either orally
or enterally, but who have to abstain from food (includ-
ing nocturnal fasting) for more then 12 hours should
receive basal glucose infusion (2–3 g/kg/d) (C). Total
PN is required if fasting periods last longer than 72 h
(C).
Commentary
The nutritional state of the patient carries a prognostic
significance in patients with ASH (III) [1], [2], [3]. Simple
bedside methods like “subjective global assessment” or
anthropometry are sufficient to identify at-risk patients,
and are, therefore, recommended [4].
PN supplementation to ad lib oral nutrition was studied
in seven controlled trials using conventional amino acid
solutions. The parenteral intake provided approximately
200–3000 kcal/d, including 35–130 g amino acids per
day, and the oral intake ranged from 13 to 39 kcal/kg/d
[5], [6], [7], [8], [9], [10], [11], [12], [13]. No change in
mortality was observed with this approach. This may be
due to the inclusion of patients with low risk and only
moderate disease severity. Adverse effects of increased
nitrogen intake were not observed, although sensitive
methods, able to detectminor degrees of hepatic enceph-
alopathy, were not used. Themajority of studies reported
an improvement in visceral protein compartment (serum
prealbumin, transferrin, total protein, total lymphocyte
count), used as a measure of the nutritional state. An
improvement in liver function (galactose elimination,
serum bilirubin) was also described.
A late evening carbohydrate snack resulted in an improve-
ment in protein metabolism in cirrhotic patients [14],
[15], [16]. Therefore, it is recommended that in the event
of a long fasting duration, patients should receive a basal
glucose intake equal to the endogenous hepatic glucose
production [14], [15], [16]. It is known that even an
overnight fast in cirrhotic patients results in depletion of
glycogen stores and metabolic conditions similar to that
after prolonged starvation in normal individuals.
Energy intake
• In practice, an energy requirement equal to 1.3 times
the basal metabolic rate, calculated by means of a
formula, can be safely assumed for patients with ASH
(C).
Commentary
According to an older study [17], ASH patients are not
different from healthy persons with regards to the rela-
tionship betweenmeasured and predicted resting energy
expenditure. ASH patients, however, show higher energy
consumption when correlated to their reduced muscle
mass (creatinine excretion in 24 h urine).
When hydration status is normal, the actual weight should
be used as body weight for the calculation of the basal
metabolic rate with the help of a formula [18]. In patients
with ascites, the ideal weight according to the body height
should be used for calculations.
Substrate intake with total PN
• Carbohydrates should be provided exclusively by
glucose and cover 50–60% of non-protein energy re-
quirements (C).
• Lipids should be provided using emulsions with a re-
duced content of polyunsaturated fatty acids compared
to pure soybean oil emulsions and cover 40–50% of
non-protein energy requirements (C).
• The amino acid intake should amount to 1.2 g/kg/d
in patients who are either not malnourished or moder-
ately malnourished, and 1.5 g/kg/d in severely mal-
nourished patients (C).
• Water-soluble and fat-soluble vitamins as well as
minerals and trace elements should be administered




These recommendations are based on those for PN in
liver cirrhosis, which is already present in many cases of
ASH. There are no systematic trials on the quantity and
the formulation of PN for ASH.
Both water-soluble and fat-soluble vitamins should be
administered daily in a standard TPN dosage. If neces-
sary, administration of pharmacological doses of vitamin
B1, as a therapy/prophylaxis for Wernicke’s encephalop-
athy, or of vitamin K in cholestasis-related fat malabsorp-
tion or other vitamins may be additionally required to
correct deficiencies. Trace elements should be admin-
istered daily in a standard total PN dose. A pragmatic
recommendation is to routinely administer double the
daily requirements of zinc (=2x10 mg/d).
This patient group is at great risk of developing refeeding
syndrome (cf. “Complications and monitoring”
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because of their tendency to be chronically malnourished.
Liver cirrhosis
Indication and time of PN in cirrhosis
• Immediate commencement of PN is indicated in cir-
rhotic patients with moderate or severe malnutrition,
who cannot be sufficiently nourished either orally or
enterally (C).
• Cirrhosis patients, who can be sufficiently nourished
either orally or enterally, but who have to abstain
temporarily from food (including nocturnal fasting) over
a 12 hour period, should receive a basal glucose infu-
sion (2–3 g/kg/d). Total PN is required if this fast lasts
longer than 72 h (C).
• PN should be considered in patients with higher-grade
hepatic encephalopathy (HE); particularly in HE IV°
with malfunction of swallowing and cough reflexes,
and unprotected airways (C).
• Cirrhosis patients should receive early postoperative
(additional) PN after surgery, notwithstanding the rec-
ommendations for other patients, if they cannot be
sufficiently nourished either orally or enterally (A).
• After liver transplantation, patients should receive early
postoperative nutrition. PN is the option second to
enteral nutrition (C).
• No recommendation can be made on the question of
donor or organ conditioning, with the aim ofminimising
ischemia/reperfusion damage, by parenteral adminis-
tration of glutamine and arginine (C).
Commentary
Numerous descriptive studies have shown higher rates
of complications and mortality in cirrhotic patients with
marked signs of protein malnutrition as well as a higher
mortality rate when subjected to liver transplantation
[19], [20], [21], [22], [23], [24], [25], [26].
Prevalence and severity of malnutrition are independent
of the aetiology of liver disease [20], [27], [28], but cor-
relate positively with the severity of the illness. The
prevalence of PEM increases from 20% in stage A, by
Child-Pugh criteria, to over 60% in stage C [27]. The daily
food intake is of prognostic significance. Cirrhosis patients
with a low, spontaneous energy intake showed the highest
mortality in controlled studies investigating the efficiency
of supplementary enteral nutrition [2], [29], [30], [31],
[32]. There are no systematic trials on PN in cirrhotic
patients without ASH.
Simple bedside methods like “Subjective Global Assess-
ment” or anthropometry were able to sufficiently identify
malnutrition, and the use of more complex score systems
was not superior in this identification [4].
The recommendation of basal glucose intake to be equal
to endogenous hepatic glucose production in the event
of longer fasting is based on the findings that a late
evening carbohydrate snack results in an improvement
in proteinmetabolism of cirrhotic patients [14], [15], [16].
After an overnight fast, in cirrhotic patients, glycogen
stores are depleted and metabolic conditions are similar
to that after prolonged starvation in normal individuals.
Hepatic Encephalopathy (HE). In patients with hepatic
encephalopathy, oral nutrition is often insufficient, even
in low-grade encephalopathy (HE I°–II°) due to somno-
lence and psycho-motor dysfunction, such that enteral
feeding is required to provide adequate nutrition. PN
should be considered in patients with higher-grade en-
cephalopathy (HE), particularly in HE IV°, when there is
malfunctioning of swallowing and cough reflexes in the
presence of unprotected airways. In clinical practice, en-
teral nutrition in patients with acute liver failure [33] and
the results of the study by Keohane et al. onmalnourished
patients with liver cirrhosis and acute encephalopathy
[34] demonstrate the feasibility of enteral nutrition in
comatose cirrhotic patients. There are no published sys-
tematic comparisons between enteral and parenteral
nutrition in patients with liver cirrhosis and encephalop-
athy.
In malnourished cirrhotic patients, the risk of
post-operative complications, including mortality, is in-
creased after abdominal operations [35].
After visceral surgery, cirrhotic patients have a lower rate
of complications when postoperative nutritional therapy
is given instead of just fluid and electrolytes [36], [37]
(Ib).
Surgery and Transplantation. Postoperative nutrition of
transplant patients confers the advantage of shorter time
onmechanical ventilation and shorter stay in the intensive
care unit compared to just fluid and electrolyte infusions
[38] (Ib). In a direct comparison between parenteral and
early enteral nutrition, both strategies were equally effi-
cient with regards to themaintenance of nutritional state
[39]. However, lower incidence of viral infections, and
improved nitrogen retention were observed in patients
who had been given early enteral nutrition, 12 hours after
the transplantation [40].
At present, the value of donor or organ conditioning, by
means of high doses of arginine intake, with the aim of
minimising ischemia/reperfusion damage is uncertain.
Energy intake
• The energy requirement of many patients with liver
cirrhosis amounts to 1.3 times the basal metabolic
rate, calculated by means of a formula (B).
Commentary
Measured resting energy expenditure is higher than pre-
dicted by the Harris Benedict formula in up to 30–35%
of cirrhotic patients (hypermetabolism), and below the
predicted value in 18% of the patients [41], [42]. Cirrhotic
patients can also have a hypermetabolic state [43],
defined as measured basal metabolic rate versus value
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calculated from measured body cell mass by regression
analysis.
In order to classify patients according to metabolic rate,
indirect calorimetry is required. Therefore, up to now these
findings remain without consequence in clinical practice.
Furthermore, the few publications on total energy expend-
iture in patients with liver cirrhosis indicate that the 24h
energy requirement of cirrhotic patients is 130% of the
basal metabolic rate [44], [45]. Diet-induced thermogen-
esis [46], [47], [48] and energy requirements for physical
activity in stable cirrhosis patients [49], [50], [51] also
show no deviation from those in healthy patients. Obvi-
ously, an increased energy requirement in advanced ill-
ness is compensated for by diminished physical activity
reflecting poor physical condition [32], [51].
When hydration status is normal, the actual weight should
be used as body weight for the calculation of the basal
metabolic rate according to a formula [18]. In patients
with ascites, the ideal weight according to body height
should be used for calculations.
Patients with liver transplantations have average energy
requirements similar to themajority of patients withmajor
abdominal surgery. In these patients too, an intake of
non-protein energy of 1.3-fold the basal metabolic rate
is generally sufficient [52], [53]. In a longitudinal study,
postoperative hypermetabolism peaked 10 days after
the transplantation at 124% of the predicted basal
metabolic rate [54]. There was no difference between
measured and predicted basal metabolic rate at 6–12
months post transplantation [54], [55]. Hyperalimentation
should be avoided.
Substrate intake – general
• If PN is used as the exclusive form of nutrition, all ne-
cessary macro- and micro-nutrients must be admin-
istered with PN (C).
• Carbohydrate intake should exclusively be provided
by glucose and cover 50–60% of non-protein energy
requirements (cf. “Carbohydrates” http://www.egms.
de/en/gms/2009-7/000082.shtml) (C).
• Lipid should be provided by using emulsions with a
reduced content of polyunsaturated fatty acids, as
compared to pure soy bean oil emulsions, and cover
40–50% of non-protein energy requirements (C).
• PN-related hyperglycaemia should be consequently
avoided (A).
• A reduction in carbohydrate intake to 2–3 g/kg/d and
continuous insulin administration, if needed, should
be carried out in case of hyperglycaemia (C).
Commentary
Insulin resistance in liver cirrhosis. In the fasting state,
substrate utilisation is characterised by an increased rate
of lipid oxidation and frequent occurrence of insulin re-
sistance, even in Child-Pugh stage A of the illness [41],
[56], [57], [58]. Insulin resistance induces reduced gluc-
ose uptake and dysfunctional non-oxidative glucose util-
isation with reduced glycogen synthesis in skeletal
muscles during fasting, while glucose oxidation and lac-
tate production return to normal after glucose administra-
tion [47], [59], [60]. Some 15–37% of cirrhotic patients
develop overt diabetes indicating an unfavourable pro-
gnosis [61], [62].
There is growing evidence of a treatment advantage in
various clinical conditions when euglycaemia is main-
tained. It seems justified to also recommend this strategy
for patients with liver cirrhosis who are receiving PN (cf.
“Carbohydrates” http://www.egms.de/en/gms/2009-7/
000082.shtml and “Intensive medicine”
http://www.egms.de/en/gms/2009-7/000073.shtml).
In the early postoperative phase, a dysfunction of glucose
metabolism associated with insulin resistance is often
prevalent. In this situation, hyperglycaemia should be
treated by reducing the glucose intake, because higher
insulin doses do not improve glucose oxidation [63].
When tacrolimus is used for immunosuppression, its
diabetogenic potential can be lowered by reducing the
dose and aiming for trough levels of 3–8 ng/ml without
undue risk of rejection [64].
Lipid tolerance andMCT/LCT. Only few data are available
on the ideal composition of the main energy-supplying
substrates, carbohydrates and lipids. Plasma clearance
and oxidation of infused lipids is normal in cirrhotic pa-
tients [65], [66]. Glucose and lipids have been used as
energy-supplying substrates in a caloric ratio of 40–50:
50–60 (G:L) in two trials [67], [68]. There are findings
suggesting more favourable substrate and metabolite
concentrations when infusing both glucose and lipid
compared to glucose as the sole energy substrate [69].
Improved functioning of the reticulo-endothelial system
was observed (cf. “Surgery and transplantation”
http://www.egms.de/en/gms/2009-7/000069.shtml)
when using MCT/LCT emulsions (with a lower content of
polyunsaturated fatty acids as compared to pure soy bean
oil emulsions) after liver transplantation.
Substrate intake – amino acids
• Amino acids should be administered in a dose of 1.2
g/kg/d in compensated cirrhosis without severe mal-
nutrition, and in a dose of 1.5 g/kg/d in decom-
pensated cirrhosis with severe malnutrition (A).
• A standard solution should be given in encephalopathy
≤ grade II and a liver-adapted complete solution should
be given in encephalopathy grades III–IV. These solu-
tions contain an increased amount of branched-chain
amino acids (BCAA) and lower content of aromatic
amino acids, methionine and tryptophan (A).
Commentary
Compensated cirrhosis. For PN, these patients do not
require an amino acid solution with a special “hepatic
formula” composition. In clinical studies, the protein or
amino acid intake in patients with liver cirrhosis and
severe encephalopathy was between 0.6 and 1.2 g/kg/d
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Table 1: Parenteral amino acid solutions with an increased content of branched-chain amino acids available in Germany
[70]. In patients with alcoholic hepatitis or cirrhosis with
or without low-grade encephalopathy, the intake was
between 0.5 and 1.6 g/kg/d [5], [6], [7], [9], [10], [11],
[12], [13], [29], [30] [31], [71]. An explicit and systematic
determination of the protein requirement has, however,
been carried out only in a few studies. In these studies,
patients with stable cirrhosis were found to have an in-
creased protein requirement of 1.2 g/kg/d in contrast to
the value of 0.8 g/kg/d in healthy humans [32], [44],
[72], [73].
Cirrhosis with encephalopathy. Liver-adapted amino acid
solutions containing increased proportions of branched-
chain (35–45%) and a reduced proportion of aromatic
amino acids as well as a reduced proportion of methio-
nine and tryptophan have been introduced for patients
with liver diseases [74], [75], [76] (Table 1). These solu-
tions help to correct the amino acid imbalance existing
in liver cirrhosis. “Coma solutions” are available in some
countries, which contain either exclusively BCAAs, or
other additional substances supposed to be effective in
hepatic encephalopathy. The solutions are incomplete,
and, therefore, should only be used to target the pharma-
cological correction of an amino acid imbalance and not
as the exclusive nitrogen source for PN.
The effectiveness of branched-chain amino acids in the
treatment of hepatic encephalopathy has been tested in
seven controlled studies [77], [78], [79], [80], [81]; the
results of which are, however, contradictory. It is extremely
difficult to detect a treatment effect on hepatic enceph-
alopathy, when at the same time complications of cir-
rhosis are present like gastrointestinal bleeding, sepsis
or renal failure, which dominate the clinical results. A
meta-analysis of these studies shows a beneficial effect
of the BCAA-enriched solutions with regards to mental
state, but not with regards to survival [70]. In a Cochrane
analysis, a subgroup of the seven randomised controlled
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studies was analysed, with a total of 397 patients with
acute hepatic encephalopathy, who were treated with
intravenously administered BCAAs in the intervention
group [82]. The parenteral BCAA administration had a
significant positive effect on the improvement of hepatic
encephalopathy; the period of survival, however, remained
unchanged.
Surgery and transplantation. After liver resection, oe-
sophagus transection with splenectomy or splenorenal
shunt in patients with liver cirrhosis, no increased enceph-
alopathy rate was observed when a conventional amino
acid solution (50 g/24 h) was used for postoperative
nutrition instead of a BCAA-enriched amino acid solution
(40 g/24 h) [37]. No difference was observed between
a standard or a BCAA-enriched amino acid solution after
liver transplantation either [38].
Transplanted patients exhibit a noteworthy nitrogen loss
with a continuously negative nitrogen balance up to 28
days post surgery [52], [83], therefore protein or amino
acid intake should be increased appropriately. A protein
or amino acid intake of 1.0–1.5 g/kg-/d wasmostly used
in studies [24], [38]. The determination of postoperative
urea-nitrogen excretion was helpful in ascertaining indi-
vidual nitrogen requirements.
Conditioning of organ donors. Data mainly derived from
experimental studies indicate that the balanced nutrition
of a “brain-dead” liver donor with moderate amounts of
carbohydrates, lipids (long-chain fatty acids and possibly
fish oil) and amino acids is associated with an improved
function of the transplanted organ [84]. The value of
donor or organ preconditioning against ischemia/reper-
fusion damage e.g. by means of high doses of arginine
is at present uncertain.
Water, electrolytes, vitamins, trace
elements
• Water, electrolytes, water- and fat-soluble vitamins as
well as trace elements should be administered daily




Patients with liver cirrhosis have profound alterations in
body composition with an increase in total body water
already in Child-Pugh stage A [85]. This goes along with
salt retention, which does notmanifest in hypernatraemia.
In contrast, potassium,magnesium, phosphate and other
intracellular minerals are frequently depleted.
No recommendations on the requirements of micronu-
trients can be made on the basis of controlled studies.
The administration of micronutrients has no effect on the
nutritional state other than in the adjustment of a defi-
ciency.
Supplementations of zinc and vitamin A might indirectly
improve the food intake and nutritional state by improving
dysgeusia [86], [87]. Zinc and selenium deficiencies were
observed in alcoholic and non-alcoholic liver disease [88],
[89], [90], [91]. A striking association between hepatic
encephalopathy and zinc deficiency has been described
in case reports [92], [93]. Oral zinc supplementation,
however, has shown no effectiveness in subclinical en-
cephalopathy in controlled studies [94], [95], [96]. Urea
production capacity increased after oral zinc supply when
the previously lowered plasma levels were normalised
[97].
A deficiency in water-soluble vitamins is common in cir-
rhosis, especially of alcoholic origin [98], [99]. Deficits in
fat-soluble vitamins are observed in cholestasis-related
steatorrhoea, bile salt deficiency and in alcoholics [100],
[101]. Supplementation with calcium and vitamin D is
recommended for patients with osteopenia, although this
did not result in any improvement in bone density in pa-
tients with primary biliary cirrhosis, with oestrogen substi-
tution proving to be much more effective in female pa-
tients [100], [102].
In practice, liberal supplementation is recommended in
the first two weeks of treatment as the laboratory diagno-
sis of a specific trace element or vitamin deficiency may
bemore expensive. Due to high prevalence ofmalnutrition
in this group of patients, they are in danger of developing
re-feeding syndrome (cf. “Complications andmonitoring”
http://www.egms.de/en/gms/2009-7/000076.shtml).
After transplantation, the often chronic hyponatraemia
should be corrected carefully in order to avoid the risk of
pontine myelinosis [103]. It is recommended to regularly
check magnesium levels in order to determine
cyclosporine- or tacrolimus-induced hypomagnesaemia
[104].
Some, but not all study groups, reported the risk of post-
operative hypophosphataemia and its possible connection
with PN following right hemihepatectomy in a living donor
[105], [106], [107].
Acute liver failure
Due to the massive loss of liver cell function, acute liver
failure is a serious condition characterised by profound
metabolic dysfunctions and almost invariably complicated
by multi-organ failure. Depending on the interval till the
onset of hepatic encephalopathy (HE), hyperacute (onset
of jaundice till HE <8 days), acute (interval <29 days) and
sub-acute liver failure (interval 29–72 days) are distin-
guished [108]. Prognosis ismore favourable in hyperacute
LF (liver failure) than in acute or subacute LF.
Despite the clinical significance of metabolic derange-
ments like hypoglycaemia or hyperammonaemia and
encephalopathy, there is only scarce animal-experiment
or physiologically descriptive data, and no published
clinical studies, on which a metabolic intervention like
nutritional therapy could be based.
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Indication and time of PN
• In analogy to intensive care patients, in acute LF artifi-
cial nutrition should be considered irrespective of the
nutritional state and should be commenced when oral
nutrition cannot be restarted within 5 to 7 days (cf.
“Intensive medicine” http://www.egms.de/en/gms/
2009-7/000073.shtml)
• Whenever possible, enteral nutrition should be admin-
istered via a nasoduodenal feeding tube (C).
Commentary
In the treatment of acute liver failure, measures to stabil-
ize themetabolism and vital functions and the treatment
of brain oedema are of utmost importance. Nutritional
therapy in this condition has two objectives:
1. ensuring the adequate provision of required energy,
especially euglycaemia, by giving glucose, lipids,
vitamins and trace elements, and
2. ensuring optimal rates of protein synthesis by
providing an adequate intake of protein or amino
acids.
Energy intake
• In acute liver failure a hypermetabolic state can occur.
The individual energy requirement should preferably,
be determined measuring energy expenditure with in-
direct calorimetry, or be estimated with a formula (C).
Commentary
Surprisingly few liver units seem to measure, or at least
calculate, the energy expenditure of patients with acute
liver failure [33] despite the well-known fact that hepatic
energy expenditure amounts to 25% of the overall energy
expenditure [109]. A survey of 33 hepatology units in
Europe showed that the resting energy expenditure was
measured by 12.5% of the centres by means of indirect
calorimetry, and that 53% usually used the Harris-Bene-
dict formula; the energy requirements were not recorded
in a third of centres.
In patients with acute liver failure, indirect calorimetry
showed an increase in resting energy expenditure, in two
studies, by 18 or 30% in comparison with healthy controls
[110], [111]. Obviously, patients with acute liver failure
are different from other critically ill patients regarding
energy expenditure (cf. “Intensive medicine”
http://www.egms.de/en/gms/2009-7/000073.shtml).
Substrate intake
• Sufficient glucose administration (2–3 g/kg/d) is
mandatory for prophylaxis or treatment of hypogly-
caemia (C). Glucose substitutes are of no proven
benefit in acute LF. Moreover, xylitol, sorbitol and
fructose have to be metabolised by the liver before
they can be utilized.
• Simultaneous infusion of glucose and lipid (0.8–1.2
g/kg/d) and offers benefits regarding insulin resistance
and should be used.
• Amino acid administration is not necessary in hyper-
acute LF. Amino acids (0.8–1.2 g/kg/d in PN) or pro-
tein (0.8–1.2 g/kg/d in enteral nutrition) should be




In LF clinically significant hypoglycaemia [112] occure
and results from a loss of hepatic gluconeogenetic cap-
acity, lack of glycogen and hyperinsulinism [113]. It is
widely accepted to treat hypoglycaemia by infusing 1.5–2
g glucose/kg body weight [114], [115]. At the end of the
1990’s, the administration of glucose doses of 6 to 10
g per kg body weight per day was practised: a blood
glucose level of under 10 mmol/l was aimed for by only
39% of centres [33]. Meanwhile, the landmark study by
v. d. Berghe showing that euglycaemic metabolic control
improved survival has likely been helpful in setting the
standard also in acute liver failure [116].
As the progress of brain oedema mainly determines the
prognosis of these patients, for pathophysiological rea-
sons, strict blood glucose control may be particularly ad-
vantageous. Increased ischemia-related damage of
neurons and glia cells [117], dysfunctional leukocyte
function [118] or oxidative stress have been found to be
associated with hyperglycaemia. The aministration of up
to 4 IU/h insulin is recommended in order to adjust blood
glucose levels and maintain euglycaemia (cf. “Carbo-
hydrates” http://www.egms.de/en/gms/2009-7/000082.
shtml and “Intensive medicine” http://www.egms.de/
en/gms/2009-7/000073.shtml).
Lipids
The oxidation of fatty acids and ketogenesis are themain
energy-providing processes for hepatocytes [119]. Thus,
adequate lipid administration would be a plausible,
therapeutic objective provided there is sufficient oxygen
supply to the liver tissues. Some cases of acute liver
failure are, however, caused by an impairment of hepatic
beta-oxidation. In these specific cases, exogenous lipid,
e.g. even administering Propofol as a sedative, cannot
be metabolised and can become potentially harmful
[120], [121]. Measurements of substrate turnover in a
study showed that there was no fatty acid absorption, but
a release of free fatty acids from the splanchnic area in
patients with acute liver failure in comparison to septic
patients [122].
There is no systematic data on the role of lipids as a nu-
trient. Exogenously administered lipids seem to be well
tolerated by most patients [123], [124]. A survey of hep-
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atology centres also showed that two-thirds of the centres
administer parenteral lipids in patients with acute liver
failure, mainly in the form of LCT/MCT emulsions [33].
Special attention should, however, be paid when giving
lipids to patients with acute liver failure and microvesicu-
lar steatosis, in whom mitochondrial dysfunction is pre-
dominant.
Monitoring should be carried out as described in the
chapter on “Complications and monitoring”
http://www.egms.de/en/gms/2009-7/000076.shtml.
Amino acids
The plasma levels of amino acids are raised 3 to 4 fold
in acute liver failure. The amino acid pattern is altered,
and shows a relative decrease in branched-chain amino
acids and a relative increase in tryptophan, aromatic and
sulphurous amino acids [125], [126], [127]. More recent
data shows that the splanchnic organs cannot take up
amino acids in the event of liver failure while a net uptake
of amino acids can be seen in healthy humans and even
in septic patients [127].
Amino acid infusion was not used as often in the past for
fear of aggravating existing hyperammonaemia and
hyperaminoacidaemia, and causing brain oedema and
encephalopathy. In the survey of hepatology centres,
more than half of the centres indicated, however, that
amino acids are infused [33]. A few centres use standard
amino acid solutions, while the majority use incomplete
solutions with branched-chain amino acids or complete
solutions enriched with branched-chain amino acids in
order to correct the altered amino acid pattern and opti-
mise the nitrogen supply [74], [128], [129].
While pathophysiological considerations provide a ra-
tionale for the use of liver-adapted solutions with an in-
creased proportion of branched-chain amino acids, no
advantage could, however, be proven in comparison to
standard solutions.
An adequate metabolic monitoring is necessary in order
to ensure substrate supply, which is adjusted for sub-
strate utilisation, and to prevent substrate overload. Strict
control of the plasma glucose levels (target: 5–8mmol/L),
lactate (target: 5.0 mmol/L), triglycerides (target: <3.0
mmol/L) and ammonia (target: <100 µmol/L) are neces-
sary for this purpose.
Patients with hypophosphataemia after acetaminophen-
induced liver damage have a better prognosis. Severe
hypophosphataemia, however, results in respiratory insuf-
ficiency and dysfunction of the nervous system and
erythrocytes [130], and thus, serum phosphate levels
should be controlled stringently and corrected in order
to support liver regeneration.
Notes
This article is part of the publication of the Guidelines on
Parenteral Nutrition from the German Society for Nutri-
tional Medicine (overview and corresponding address
under http://www.egms.de/en/gms/2009-7/000086.
shtml).
English version edited by Sabine Verwied-Jorky, Rashmi
Mittal and Berthold Koletzko, Univ. of Munich Medical
Centre, Munich, Germany.
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